Filter
72
Featured
16
4
Language
Document type
37
11
10
4
4
3
2
1
Countries / Regions
5
4
2
2
1
1
1
1
1
Authors & Publishers
Publication Years
Category
15
3
2
Treatment and care in children and adolescents
recommended
WHO recommends that infants born to mothers living with HIV are tested for HIV by two months of age, during breastfeeding, and when breastfeeding ends given continued risk of transmission during this period. Older children, especially offspring and siblings of persons infected with HIV, should also
...
This brief report summarizes recent information on HIV drug resistance (HIVDR) in the era of integrase-strand transfer inhibitors (INSTI) for HIV prevention and treatment.
A job aid for cadres supporting adolescents living with HIV (ages 15-19) in Orphans and Vulnerable
Children (OVC) Programs
CDC leads an international surveillance effort to estimate the occurrence of HIV drug resistance among people with HIV who are taking dolutegravir (DTG)-based treatments. This surveillance effort utilizes Cyclical Acquired HIV Drug Resistance Surveillance (CADRE), a laboratory-based HIV drug resista
...
The HIV care continuum is a public health model that outlines the steps or stages that people with HIV go through from diagnosis to achieving and maintaining viral suppression (a very low or undetectable amount of HIV in the body).
A job aid for cadres supporting caregivers of children and adolescents living with HIV (ages 0-14) in Orphans and Vulnerable Children (OVC) Programs
JAMA. 2025;333(7):609–628. doi:10.1001/jama.2024.24543
PARTICIPANT GUIDE.
This Participant Guide has been designed to assist health facilities and community based non-clinicians to develop skills to provide linkage to care, adherence and retention in care services for chronic conditions
Avec l’essor des traitements antirétroviraux (TAR) à base de dolutégravir (DTG) pour soigner les personnes vivant avec le VIH dans le monde, il est important d’estimer la vitesse à laquelle la résistance acquise au DTG apparaît dans les populations sous TAR. Bien que la résistance au DTG
...
A medida que el tratamiento antirretrovírico con dolutegravir se extiende a más personas que viven con el VIH en el mundo, adquiere más importancia estimar la frecuencia con que surge la farmacorresistencia adquirida a este antirretrovírico en las poblaciones tratadas con esquemas que lo contien
...
During ARV drug pressure the HIV-1 RT is able to develop resistance to these drugs by generating mutations
July 2023 version .The 2023 ART guideline introduces simplified ART provision and harmonised methods of management of children, adolescents and adults, as well as pregnant women living with HIV/AIDS, TB and other common opportunistic infections.
The guidelines also provide guidance on the use of D
...
This report aims to provide countries and suppliers with estimates of the global market for antiretroviral (ARV) medicines in low- and middle-income countries for 2021–2025. The report includes estimates of the global demand for active pharmaceutical ingredients (APIs) and ARV formulations for adu
...
This technical report summarizes the discussions on the status of programmatic transition to tenofovir, lamivudine and dolutegravir (TLD) in low– and middle- income countries, addressing the best practices and major challenges faced by HIV programmes.
The latest data on safety and efficacy of do
...
WHO’s sentinel surveys of acquired HIV resistance to dolutegravir among people receiving dolutegravir-containing antiretroviral therapy is intended for easy and frequent implementation. Results from sentinel surveys provide insight into the prevalence and year-over-year trends of dolutegravir resi
...
The indicators and questions in this document are designed for use by national AIDS programmes and partners to assess the state of a country’s HIV and AIDS response, and to measure progress towards achieving national HIV targets. Countries are encouraged to integrate these indicators and questions
...
Open Forum Infect Dis . 2022 Apr 5;9(5):ofac148.doi: 10.1093/ofid/ofac148. eCollection 2022 May. Dolutegravir HIV drug resistance (HIVDR) data from Africa remain sparse. We reviewed HIVDR results of Malawians on dolutegravir-based antiretroviral therapy (November 2020– September 2021). Of 6462 eli
...
ATIC Newsletter, Vol 15, Issue 1,
February 2022.
These guidelines, produced in 2022 by the Uganda Ministry of Health, provide guidance on the diagnosis of HIV, the care of people living with HIV, and the use of antiretroviral drugs for treating and preventing HIV infection, including injectable cabotegravir and the dapivirine vaginal ring.
